{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T12:30:14Z","timestamp":1791117014167,"version":"4.1.0"},"reference-count":86,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2012,1,11]],"date-time":"2012-01-11T00:00:00Z","timestamp":1326240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,1,11]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>OTHER THEMES PUBLISHED IN THIS IMMUNOLOGY IN THE CLINIC REVIEW SERIES<\/jats:p>\n               <jats:p>Metabolic Diseases, Host Responses, Allergies, Autoinflammatory Diseases, Type 1 diabetes and viruses.<\/jats:p>\n               <jats:p>Despite complex genomic and epigenetic abnormalities, many cancers are irrevocably dependent on an initiating oncogenic lesion whose restoration to a normal physiological activation can elicit a dramatic and sudden reversal of their neoplastic properties. This phenomenon of the reversal of tumorigenesis has been described as oncogene addiction. Oncogene addiction had been thought to occur largely through tumour cell-autonomous mechanisms such as proliferative arrest, apoptosis, differentiation and cellular senescence. However, the immune system plays an integral role in almost every aspect of tumorigenesis, including tumour initiation, prevention and progression as well as the response to therapeutics. Here we highlight more recent evidence suggesting that oncogene addiction may be integrally dependent upon host immune-mediated mechanisms, including specific immune effectors and cytokines that regulate tumour cell senescence and tumour-associated angiogenesis. Hence, the host immune system is essential to oncogene addiction.<\/jats:p>","DOI":"10.1111\/j.1365-2249.2011.04514.x","type":"journal-article","created":{"date-parts":[[2011,10,31]],"date-time":"2011-10-31T15:33:47Z","timestamp":1320075227000},"page":"188-194","source":"Crossref","is-referenced-by-count":22,"title":["Immunology in the clinic review series; focus on cancer: multiple roles for the immune system in oncogene addiction"],"prefix":"10.1093","volume":"167","author":[{"given":"P","family":"Bachireddy","sequence":"first","affiliation":[{"name":"Department of Medicine, Brigham and Women's Hospital\/Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Rakhra","sequence":"additional","affiliation":[{"name":"Division of Oncology, Departments of Medicine and Pathology, Stanford University School of Medicine, Stanford, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D W","family":"Felsher","sequence":"additional","affiliation":[{"name":"Division of Oncology, Departments of Medicine and Pathology, Stanford University School of Medicine, Stanford, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,1,11]]},"reference":[{"key":"2021122708460205700_b1","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nrc1070","article-title":"Cancer revoked: oncogenes as therapeutic targets","volume":"3","author":"Felsher","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"2021122708460205700_b2","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1158\/0008-5472.CAN-07-3293","article-title":"Oncogene addiction","volume":"68","author":"Weinstein","year":"2008","journal-title":"Cancer Res"},{"key":"2021122708460205700_b3","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1101\/gad.1609907","article-title":"Oncogene addiction: setting the stage for molecularly targeted cancer therapy","volume":"21","author":"Sharma","year":"2007","journal-title":"Genes Dev"},{"key":"2021122708460205700_b4","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1097-2765(00)80367-6","article-title":"Reversible tumorigenesis by MYC in hematopoietic lineages","volume":"4","author":"Felsher","year":"1999","journal-title":"Mol Cell"},{"key":"2021122708460205700_b5","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1126\/science.1071489","article-title":"Sustained loss of a neoplastic phenotype by brief inactivation of MYC","volume":"297","author":"Jain","year":"2002","journal-title":"Science"},{"key":"2021122708460205700_b6","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/nature03043","article-title":"MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer","volume":"431","author":"Shachaf","year":"2004","journal-title":"Nature"},{"key":"2021122708460205700_b7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/71691","article-title":"Reversibility of acute B-cell leukaemia induced by BCR-ABL1","volume":"24","author":"Huettner","year":"2000","journal-title":"Nat Genet"},{"key":"2021122708460205700_b8","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/22788","article-title":"Essential role for oncogenic Ras in tumour maintenance","volume":"400","author":"Chin","year":"1999","journal-title":"Nature"},{"key":"2021122708460205700_b9","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1158\/0008-5472.CAN-05-2720","article-title":"Oncogenic BRAF is required for tumor growth and maintenance in melanoma models","volume":"66","author":"Hoeflich","year":"2006","journal-title":"Cancer Res"},{"key":"2021122708460205700_b10","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ccr.2004.10.013","article-title":"Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation","volume":"6","author":"Boxer","year":"2004","journal-title":"Cancer Cell"},{"key":"2021122708460205700_b11","doi-asserted-by":"crossref","first-page":"13028","DOI":"10.1073\/pnas.0701953104","article-title":"Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation","volume":"104","author":"Wu","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122708460205700_b12","doi-asserted-by":"crossref","first-page":"16266","DOI":"10.1073\/pnas.0608017103","article-title":"Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch","volume":"103","author":"Giuriato","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122708460205700_b13","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1101\/gad.1455706","article-title":"The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1beta","volume":"20","author":"Shchors","year":"2006","journal-title":"Genes Dev"},{"key":"2021122708460205700_b14","doi-asserted-by":"crossref","first-page":"e2125","DOI":"10.1371\/journal.pone.0002125","article-title":"Combined inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas","volume":"3","author":"Tran","year":"2008","journal-title":"PLoS ONE"},{"key":"2021122708460205700_b15","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1158\/0008-5472.CAN-08-3836","article-title":"Targeted cancer therapeutics","volume":"69","author":"Hait","year":"2009","journal-title":"Cancer Res"},{"key":"2021122708460205700_b16","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/nature03095","article-title":"Targeted cancer therapy","volume":"432","author":"Sawyers","year":"2004","journal-title":"Nature"},{"key":"2021122708460205700_b17","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"2021122708460205700_b18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab \u2013 mechanism of action and use in clinical practice","volume":"357","author":"Hudis","year":"2007","journal-title":"N Engl J Med"},{"key":"2021122708460205700_b19","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"2021122708460205700_b20","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMct0807960","article-title":"Treatment of non-small-cell lung cancer with erlotinib or gefitinib","volume":"364","author":"Cataldo","year":"2011","journal-title":"N Engl J Med"},{"key":"2021122708460205700_b21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1126\/science.1073096","article-title":"Cancer. Addiction to oncogenes \u2013 the Achilles heel of cancer","volume":"297","author":"Weinstein","year":"2002","journal-title":"Science"},{"key":"2021122708460205700_b22","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.gde.2003.12.008","article-title":"Reversibility of oncogene-induced cancer","volume":"14","author":"Felsher","year":"2004","journal-title":"Curr Opin Genet Dev"},{"key":"2021122708460205700_b23","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.4161\/cc.5.24.3598","article-title":"Oncogenic shock: turning an activated kinase against the tumor cell","volume":"5","author":"Sharma","year":"2006","journal-title":"Cell Cycle"},{"key":"2021122708460205700_b24","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nrc1691","article-title":"The concept of synthetic lethality in the context of anticancer therapy","volume":"5","author":"Kaelin","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"2021122708460205700_b25","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nrc2067","article-title":"The tumour microenvironment as a target for chemoprevention","volume":"7","author":"Albini","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"2021122708460205700_b26","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"2021122708460205700_b27","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0092-8674(00)00139-2","article-title":"MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis","volume":"103","author":"Coussens","year":"2000","journal-title":"Cell"},{"key":"2021122708460205700_b28","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/35094059","article-title":"Putting tumours in context","volume":"1","author":"Bissell","year":"2001","journal-title":"Nat Rev Cancer"},{"key":"2021122708460205700_b29","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0140-6736(00)04046-0","article-title":"Inflammation and cancer: back to Virchow?","volume":"357","author":"Balkwill","year":"2001","journal-title":"Lancet"},{"key":"2021122708460205700_b30","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ccr.2005.04.014","article-title":"De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent","volume":"7","author":"de Visser","year":"2005","journal-title":"Cancer Cell"},{"key":"2021122708460205700_b31","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1172\/JCI44796","article-title":"A dual role for the immune response in a mouse model of inflammation-associated lung cancer","volume":"121","author":"Dougan","year":"2011","journal-title":"J Clin Invest"},{"key":"2021122708460205700_b32","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/35074122","article-title":"IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity","volume":"410","author":"Shankaran","year":"2001","journal-title":"Nature"},{"key":"2021122708460205700_b33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cytogfr.2009.11.002","article-title":"Lymphocytes in cancer development: polarization towards pro-tumor immunity","volume":"21","author":"Ruffell","year":"2010","journal-title":"Cytokine Growth Factor Rev"},{"key":"2021122708460205700_b34","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat Immunol"},{"key":"2021122708460205700_b35","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"2021122708460205700_b36","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nrc1782","article-title":"Paradoxical roles of the immune system during cancer development","volume":"6","author":"de Visser","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"2021122708460205700_b37","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ccr.2009.12.019","article-title":"FcRgamma activation regulates inflammation-associated squamous carcinogenesis","volume":"17","author":"Andreu","year":"2010","journal-title":"Cancer Cell"},{"key":"2021122708460205700_b38","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.0022-202X.2004.22342.x","article-title":"Characterizing the protective component of the alphabeta T cell response to transplantable squamous cell carcinoma","volume":"122","author":"Girardi","year":"2004","journal-title":"J Invest Dermatol"},{"key":"2021122708460205700_b39","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1084\/jem.193.6.727","article-title":"Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy","volume":"193","author":"Lin","year":"2001","journal-title":"J Exp Med"},{"key":"2021122708460205700_b40","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1084\/jem.188.12.2357","article-title":"The central role of CD4(+) T cells in the antitumor immune response","volume":"188","author":"Hung","year":"1998","journal-title":"J Exp Med"},{"key":"2021122708460205700_b41","doi-asserted-by":"crossref","first-page":"7090","DOI":"10.1158\/0008-5472.CAN-08-0643","article-title":"Thrombospondin 1 promotes tumor macrophage recruitment and enhances tumor cell cytotoxicity of differentiated U937 cells","volume":"68","author":"Martin-Manso","year":"2008","journal-title":"Cancer Res"},{"key":"2021122708460205700_b42","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ccr.2009.12.043","article-title":"Tumor stroma-derived TGF-beta limits Myc-driven lymphomagenesis via Suv39h1-dependent senescence","volume":"17","author":"Reimann","year":"2010","journal-title":"Cancer Cell"},{"key":"2021122708460205700_b43","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/CJI.0b013e3181ee6ba9","article-title":"Mature B cells are critical to T-cell-mediated tumor immunity induced by an agonist anti-GITR monoclonal antibody","volume":"33","author":"Zhou","year":"2010","journal-title":"J Immunother"},{"key":"2021122708460205700_b44","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0065-230X(03)90004-2","article-title":"Natural killer cells and cancer","volume":"90","author":"Wu","year":"2003","journal-title":"Adv Cancer Res"},{"key":"2021122708460205700_b45","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2009.06.018","article-title":"CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages","volume":"16","author":"DeNardo","year":"2009","journal-title":"Cancer Cell"},{"key":"2021122708460205700_b46","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.cell.2006.01.007","article-title":"Macrophages: obligate partners for tumor cell migration, invasion, and metastasis","volume":"124","author":"Condeelis","year":"2006","journal-title":"Cell"},{"key":"2021122708460205700_b47","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"key":"2021122708460205700_b48","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cell.2004.07.013","article-title":"IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer","volume":"118","author":"Greten","year":"2004","journal-title":"Cell"},{"key":"2021122708460205700_b49","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJM199011013231802","article-title":"Ulcerative colitis and colorectal cancer. A population-based study","volume":"323","author":"Ekbom","year":"1990","journal-title":"N Engl J Med"},{"key":"2021122708460205700_b50","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/j.1349-7006.2003.tb01392.x","article-title":"CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers","volume":"94","author":"Wakabayashi","year":"2003","journal-title":"Cancer Sci"},{"key":"2021122708460205700_b51","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.jhep.2008.12.033","article-title":"Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients","volume":"50","author":"Zhang","year":"2009","journal-title":"J Hepatol"},{"key":"2021122708460205700_b52","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"key":"2021122708460205700_b53","first-page":"2","article-title":"Concordant down-regulation of proto-oncogene PML and major histocompatibility antigen HLA class I expression in high-grade prostate cancer","volume":"3","author":"Zhang","year":"2003","journal-title":"Cancer Immun"},{"key":"2021122708460205700_b54","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/24628","article-title":"Proto-oncogene PML controls genes devoted to MHC class I antigen presentation","volume":"396","author":"Zheng","year":"1998","journal-title":"Nature"},{"key":"2021122708460205700_b55","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1084\/jem.20051848","article-title":"The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells","volume":"203","author":"Sumimoto","year":"2006","journal-title":"J Exp Med"},{"key":"2021122708460205700_b56","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1158\/0008-5472.CAN-10-0118","article-title":"Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function","volume":"70","author":"Boni","year":"2010","journal-title":"Cancer Res"},{"key":"2021122708460205700_b57","doi-asserted-by":"crossref","first-page":"14825","DOI":"10.1073\/pnas.0503039102","article-title":"Induction of a proinflammatory program in normal human thyrocytes by the RET\/PTC1 oncogene","volume":"102","author":"Borrello","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122708460205700_b58","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1101\/gad.1549407","article-title":"Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis","volume":"21","author":"Ancrile","year":"2007","journal-title":"Genes Dev"},{"key":"2021122708460205700_b59","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ccr.2004.09.028","article-title":"Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis","volume":"6","author":"Sparmann","year":"2004","journal-title":"Cancer Cell"},{"key":"2021122708460205700_b60","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1101\/gad.2038411","article-title":"Endogenous Myc maintains the tumor microenvironment","volume":"25","author":"Sodir","year":"2011","journal-title":"Genes Dev"},{"key":"2021122708460205700_b61","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrclinonc.2010.223","article-title":"Immune parameters affecting the efficacy of chemotherapeutic regimens","volume":"8","author":"Zitvogel","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"2021122708460205700_b62","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science"},{"key":"2021122708460205700_b63","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"key":"2021122708460205700_b64","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nrc797","article-title":"AIDS-related malignancies","volume":"2","author":"Boshoff","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"2021122708460205700_b65","doi-asserted-by":"crossref","first-page":"5383","DOI":"10.1158\/0008-5472.CAN-08-3845","article-title":"Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas","volume":"69","author":"Ray-Coquard","year":"2009","journal-title":"Cancer Res"},{"key":"2021122708460205700_b66","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/nm1649","article-title":"Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors","volume":"13","author":"Soucek","year":"2007","journal-title":"Nat Med"},{"key":"2021122708460205700_b67","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10911-010-9194-9","article-title":"The tumor-immune microenvironment and response to radiation therapy","volume":"15","author":"Shiao","year":"2010","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"2021122708460205700_b68","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat Med"},{"key":"2021122708460205700_b69","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ccr.2010.10.002","article-title":"CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation","volume":"18","author":"Rakhra","year":"2010","journal-title":"Cancer Cell"},{"key":"2021122708460205700_b70","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ccr.2010.11.002","article-title":"Can antitumor immunity help to explain \u2018oncogene addiction\u2019?","volume":"18","author":"Restifo","year":"2010","journal-title":"Cancer Cell"},{"key":"2021122708460205700_b71","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.cell.2008.03.038","article-title":"Chemokine signaling via the CXCR2 receptor reinforces senescence","volume":"133","author":"Acosta","year":"2008","journal-title":"Cell"},{"key":"2021122708460205700_b72","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.4049\/jimmunol.166.4.2276","article-title":"IFN-gamma-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-gamma","volume":"166","author":"Beatty","year":"2001","journal-title":"J Immunol"},{"key":"2021122708460205700_b73","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.cell.2008.03.039","article-title":"Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network","volume":"133","author":"Kuilman","year":"2008","journal-title":"Cell"},{"key":"2021122708460205700_b74","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ccr.2008.04.001","article-title":"TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis","volume":"13","author":"Muller-Hermelink","year":"2008","journal-title":"Cancer Cell"},{"key":"2021122708460205700_b75","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/1521-4141(200204)32:4<1069::AID-IMMU1069>3.0.CO;2-E","article-title":"T lymphocyte expression of thrombospondin-1 and adhesion to extracellular matrix components","volume":"32","author":"Li","year":"2002","journal-title":"Eur J Immunol"},{"key":"2021122708460205700_b76","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1182\/blood-2006-04-016832","article-title":"Endogenous thrombospondin-1 is a cell-surface ligand for regulation of integrin-dependent T-lymphocyte adhesion","volume":"108","author":"Li","year":"2006","journal-title":"Blood"},{"key":"2021122708460205700_b77","doi-asserted-by":"crossref","first-page":"47633","DOI":"10.1074\/jbc.M404918200","article-title":"The tryptophan-rich motifs of the thrombospondin type 1 repeats bind VLAL motifs in the latent transforming growth factor-beta complex","volume":"279","author":"Young","year":"2004","journal-title":"J Biol Chem"},{"key":"2021122708460205700_b78","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.immuni.2004.07.020","article-title":"TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling","volume":"21","author":"Becker","year":"2004","journal-title":"Immunity"},{"key":"2021122708460205700_b79","doi-asserted-by":"crossref","first-page":"8643","DOI":"10.1158\/0008-5472.CAN-07-0982","article-title":"Transforming growth factor-beta can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cell and committed progeny in a breast cancer xenograft model","volume":"67","author":"Tang","year":"2007","journal-title":"Cancer Res"},{"key":"2021122708460205700_b80","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1101\/gad.585710","article-title":"The interaction between Myc and Miz1 is required to antagonize TGFbeta-dependent autocrine signaling during lymphoma formation and maintenance","volume":"24","author":"van Riggelen","year":"2010","journal-title":"Genes Dev"},{"key":"2021122708460205700_b81","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.coi.2009.02.004","article-title":"Adoptive immunotherapy of cancer using CD4(+) T cells","volume":"21","author":"Muranski","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"2021122708460205700_b82","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nature05529","article-title":"Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas","volume":"445","author":"Xue","year":"2007","journal-title":"Nature"},{"key":"2021122708460205700_b83","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nrc2256","article-title":"Models, mechanisms and clinical evidence for cancer dormancy","volume":"7","author":"Aguirre-Ghiso","year":"2007","journal-title":"Nat Rev"},{"key":"2021122708460205700_b84","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/nrc3057","article-title":"Pro-senescence therapy for cancer treatment","volume":"11","author":"Nardella","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"2021122708460205700_b85","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nrclinonc.2011.66","article-title":"Targeted therapies: peaking beneath the surface of recent bevacizumab trials","volume":"8","author":"Gonzalez-Angulo","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"2021122708460205700_b86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CJI.0b013e3181b88ffc","article-title":"Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells","volume":"33","author":"Wrzesinski","year":"2010","journal-title":"J Immunother"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2249.2011.04514.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/167\/2\/188\/41907976\/j.1365-2249.2011.04514.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/167\/2\/188\/41907976\/j.1365-2249.2011.04514.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T16:26:01Z","timestamp":1641054361000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/167\/2\/188\/6422821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,11]]},"references-count":86,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2012,1,11]]},"published-print":{"date-parts":[[2012,1,11]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2249.2011.04514.x","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,2]]},"published":{"date-parts":[[2012,1,11]]}}}